Finafta Spray
NDC 58593-782
Product Information
Finafta (benzocaine) is a OTC MONOGRAPH DRUG-approved product labeled by Efficient Laboratories Inc.. This medication is typically used as a allergens [cs]. It is supplied as a spray for oral administration. This product entry covers the primary NDC 58593-782 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 58593-782?
What are the uses of this product?
What are Active Ingredients of this product?
- BENZOCAINE 7.5 mg/100mL - A surface anesthetic that acts by preventing transmission of impulses along NERVE FIBERS and at NERVE ENDINGS.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- BENZOCAINE (UNII: U3RSY48JW5)
- BENZOCAINE (UNII: U3RSY48JW5) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- BENZALKONIUM CHLORIDE (UNII: F5UM2KM3W7)
- METHYLPARABEN (UNII: A2I8C7HI9T)
- PEPPERMINT OIL (UNII: AV092KU4JH)
- PHOSPHORIC ACID (UNII: E4GA8884NN)
- PROPYLENE GLYCOL (UNII: 6DC9Q167V3)
- PROPYLPARABEN (UNII: Z8IX2SC1OH)
- WATER (UNII: 059QF0KO0R)
- GLYCERIN (UNII: PDC6A3C0OX)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1110816 - benzocaine 7.5 % Mucosal Spray
- RxCUI: 1110816 - benzocaine 75 MG/ML Mucosal Spray
- RxCUI: 1110820 - Finafta Multi Oral 7.5 % Mucosal Spray
- RxCUI: 1110820 - benzocaine 75 MG/ML Mucosal Spray [Finafta Multi Oral]
- RxCUI: 1110820 - Finafta Multi Oral 75 MG/ML Mucosal Spray
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.